No Evidence of Harms of Probiotic Lactobacillus rhamnosus GG ATCC 53103 in Healthy Elderly—A Phase I Open Label Study to Assess Safety, Tolerability and Cytokine Responses

BACKGROUND: Although Lactobacillus rhamnosus GG ATCC 53103 (LGG) has been consumed by 2 to 5 million people daily since the mid 1990s, there are few clinical trials describing potential harms of LGG, particularly in the elderly. OBJECTIVES: The primary objective of this open label clinical trial is...

Descripción completa

Detalles Bibliográficos
Autores principales: Hibberd, Patricia L., Kleimola, Lauren, Fiorino, Anne-Maria, Botelho, Christine, Haverkamp, Miriam, Andreyeva, Irina, Poutsiaka, Debra, Fraser, Claire, Solano-Aguilar, Gloria, Snydman, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249962/
https://www.ncbi.nlm.nih.gov/pubmed/25438151
http://dx.doi.org/10.1371/journal.pone.0113456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249962/
https://www.ncbi.nlm.nih.gov/pubmed/25438151
http://dx.doi.org/10.1371/journal.pone.0113456

Ejemplares similares